Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Real-Life Human Factors Validation
NCT02682823Phase 4Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Jul 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, open-label trial of tocilizumab in rheumatoid arthritis (RA) (5 arms), sponsored by Roche. Primary endpoints: Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use at Day 14 and Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use at Day 28. Started Mar 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02682823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682823.